Areas of Study

SCTRO is currently conducting multiple clinical trials in the following therapeutic areas:

Dry Eye Syndrome

Dry eye syndrome is caused by lack of sufficient lubrication and moisture on the surface of the eye. Over time, the consequences of dry eyes can result in constant eye irritation to significant inflammation and even scarring on the front surface of the eye. It is considered one of the most common eye conditions worldwide. Risk factors include advanced age, female sex, and computer use.

Glaucoma

Glaucoma is a group of eye diseases which can damage the optic nerve (the nerve connecting the eye to the brain) and lead to progressive, irreversible loss of vision. It is almost always usually caused by too much pressure inside one or both eyes. Risk factors include advanced age, family history of glaucoma, medical conditions such as heart disease, diabetes, high blood pressure, and certain races are more susceptible.

Post Cataract - Anti- Inflammatory

Favorable outcomes after cataract surgery depends on proper control of the inflammatory response induced by the procedure. Inflammation after cataract surgery is an uncomfortable complication but a little swelling and redness is normal.

Diabetic Macular Edema (DME)

When you have diabetes, you can suffer other conditions that affect your eyes. Diabetic macular edema is caused by ongoing damage to the small blood vessels of the retina. DME doesn’t always cause symptoms so it is important to get your eyes checked every year. High blood sugar weakens the blood vessels in your eyes. That can cause fluid to leak into your retina, which is the light-sensitive tissue in the back of the eye. The leaking makes the retina swell and impacts function of the macula, which is responsible for sharp, straight-ahead vision. The primary symptom of DME is blurry or wavy vision. Colors may also appear washed out or faded.

Diabetes

Diabetes is a condition that impairs the body’s ability to process blood glucose, or your body’s blood sugar due to problems with the hormone insulin. Insulin is produced by the pancreas and helps your body use and store the sugars and fat from the food you eat. When the pancreas produces little to no insulin, or if the body does not respond appropriately to insulin, diabetes can occur. Without ongoing and careful management, high blood sugar levels can lead to serious health problems, including diabetic retinopathy and diabetic macular edema.

Alzheimer’s Disease

Alzheimer’s disease, a common form of dementia, is a progressive disease that destroys memory and causes brain cells to atrophy, or waste away and die. It impacts the parts of the brain that control thought, memory, and language. As the disease progresses over time, it can seriously affect a person’s ability to carry out daily activities. Anyone can get Alzheimer’s but certain people are at higher risk.
Those with advanced age and family history are the main factors, but research has linked moderate to severe traumatic brain injury to a greater risk of developing Alzheimer’s as well.

Clinical Trials

Dry Eye Disease Associated with Meibomian Gland Dysfunction

This is a study for anyone who has a reported history of Dry Eye Disease with Meibomian Gland Dysfunction. You must have been dealing with this for at least 6 months prior to screening.

Gender: M or F
Age: 18 yrs and older
Study Duration: 5 visits over approximately 10 weeks

Study Details:
1. No pregnant, nursing, or planning a pregnancy
2. No contact lens wear within 1 month of Screening or plan to use during the trial

Open Angle Glaucoma or Ocular Hypertension

This is a study for adults suffering from chronic open angle glaucoma or ocular hypertension in both eyes.

Gender: M or F
Age: 18 yrs and older
Study Duration: 6 weeks

Study Details:
1. Subjects who require treatment of both eyes and can discontinue use of all OH medications or switch and undergo appropriate washout period
2. Baseline IOP of ≥ 22 mm Hg and ≤ 34 mm Hg in each eye. Asymmetry of IOP between the eyes no greater than 5 mm Hg
3. No pregnant, nursing, or planning a pregnancy
4. No presence of any clinically significant condition or illness that would interfere with the study evaluations or optimal participation
5. No any other form of glaucoma
6. Functionally significant visual field loss

Dry Eye Disease

For those who must use, or feel the need to use artificial tears/gel/lubricants on a regular basis. This is a study for adults who have been diagnosed by a physician with Dry Eye Disease in both eyes. You must have been diagnosed a minimum of 6 months prior to screening with us.

Gender: M or F
Age: 18 yrs and older
Study Duration: Approximately 60 days

Study Details:
1. No currently active or history of ocular allergies during the time of study participation
2. Must have chronic, stable medication history for at least 30 days prior to Screening
3. No intraocular surgery within 6 months prior to Screening

Other Clinical Research Studies

  • A Phase Ilb/lll, Multicenter, Dose Selection, Randomized, Double-Masked, Placebo- Controlled Study of *** for Reduction of Lower Lid Steatoblepharon 

  • A Phase III Multi-Center, Randomized, Double-Masked, Active and Placebo- Controlled Study of *** in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma 

  • A Phase II, Vehicle-Controlled, Randomized, Dose-ranging Study of the Safety, Efficacy, Tolerability, and Systemic Pharmacokinetics of *** Ophthalmic Suspension in Patients with Dry Eye Disease 

  • A Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Safety and Efficacy of *** in Patients with Acute Anterior Uveitis 

  • A Randomized, Double-Masked, Vehicle-Controlled Study of *** in the Relief of Persistent Ocular Discomfort in Patients with Severe Dry Eye Disease 

  • A Multicenter, Double-Masked, Randomized, One-Year Safety Study of *** Topical Ophthalmic Solution vs *** in Subjects with Dry Eye Disease (DED) 

  • A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of *** Transdermal System (TDS) as Compared to *** TDS in Adult Patients with a Chalazion 

  • A Randomized, Placebo-Controlled, Double-Masked, Multiple-Ascending-Dose, Phase 1 Study to Assess the Safety and Tolerability of *** Applied to the Periorbital Skin of Healthy Volunteers. 

  • A Phase II, Multi-center, Double-masked. Randomized, Vehicle-controlled comparison of the Safety and Efficacy of Concurrently Used *** and *** in Patients with Presbyopia 

  • Crossed Precision Design Study of ***, *** and *** for the Measurements of Retinal RNFL Thickness, Optic Disc Analysis, and Pachymetry. 

  • A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of *** for Reduction of Submental Fat 

  • A Phase Ila, Randomized, Double-Blind, Placebo-Controlled Study of *** for Reduction of Lower Lid Steatoblepharon 

  • A Double-Masked, Placebo-Controlled, Dose-Escalation Study & Double-Masked, Two Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of *** in Patients with Ocular Hypertension or Mild Open-Angle Glaucoma 

  • A Phase I, Randomized, Double-Blind, Placebo-Controlled. Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of *** in Healthy Japanese Subjects 

  • Randomized, Double-Masked, Vehicle-Controlled, Multiple-Dose and Safety Pharmacokinetic Study of *** Ophthalmic Solution, *** Following Topical Ocular Administration in Healthy Normal Subjects 

  • Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study of the Effect on Cognitive Performance, Safety and Tolerability of *** in Patients with Mild to Moderate Alzheimer's Disease on Stable *** 

  • Evaluation of Efficacy and Safety of an *** with a Contact Lens in the Treatment of Allergic Conjunctivitis 

  • Evaluation of Efficacy of *** in Seasonal Allergic Conjunctivitis 

  • Topical Application of *** for the Treatment of Corneal Epithelium Defect After Ocular Surgeries 

  • Efficacy and Safety of a Study Medication for the Treatment of Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion 

  • Efficacy Study of *** Combination Treatment of Diabetic Macular Edema 

  • Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification 

  • Ophthalmologic Safety Study of *** compared to *** in Routine Cataract Surgery 

  • Efficacy of an Ophthalmic Emulsion Compared with another medication in Meibomian Gland Dysfunction 

  • A Randomized, Double-Masked, Vehicle-Controlled Study of *** in the Relief of Persistent Ocular Discomfort in Patients with Severe Dry Eye Disease. 

  • A Multicenter, Randomized, Double-masked. Active-controlled Study to Evaluate the Safety and Efficacy of *** in Patients with Acute Anterior Uveitis. 

  • A Phase II, Vehicle-controlled, Randomized, Dose-ranging Study of the Safety, Efficacy, Tolerability, and Systemic Pharmacokinetics of *** in Patients with Dry Eye Disease. 

  • A Phase IIb/III, Multi-Center, Dose-Selection, Randomized, Double-Masked, Placebo-Controlled Study of *** for Reduction of Lower Lid Steatoblepharon. 

  • A Comparison of *** to *** in Patients with Open-Angle Glaucoma or Ocular Hypertension. 

  • The Efficacy and Safety of *** in Patients with Open-angle Glaucoma or Ocular Hypertension. 

  • A Phase II, Multicenter, Double-masked, Randomized, Vehicle-Controlled. Study of the Concurrent Use of *** and *** in Patients with Presbyopia. 

  • A Phase II, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of *** and *** in Patients with Presbyopia. 

  • A Phase II. Randomized. Double-masked Study to Evaluate the Efficacy, Safety and Tolerability of Topical Ocular Administration of Fixed-Dose Combinations of *** and *** in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma. 

  • A Safety and PK Bridging Trial of *** and *** Comparing First Generation Japanese Subjects and non-Japanese Subjects. 

  • A Randomized, Double-masked, Placebo-controlled Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Daily and Multiple Daily Ascending Doses of *** Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-angle Glaucoma (POAG). 

  • A Phase III, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of *** (*** and ***) Ophthalmic Suspension Compared to *** and Placebo in the Treatment of Adenoviral Conjunctivitis. 

  • A Phase III, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of ***(*** and ***) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis. 

  • A Double-Masked, Randomized, Multicenter, Placebo-Controlled. Parallel-Group Study of *** Ophthalmic Solution Compared with Placebo to Assess Safety and Efficacy of Two Dose 

  • Concentrations of *** Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients with Moderate to Severe Corneal Epithelial Disorders. 

  • A Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of *** Drug Product in Healthy Adult Subjects. 

  • Monitor blood pressure during daily living and overnight during sleep. 

  • A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of *** Administered to Healthy Japanese and Caucasian subjects. 

  • A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics. Pharmacodynamics, Safety, and Tolerability of Second Generation *** Administered to Healthy Subjects. 

  • An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of *** in Healthy Participants 

  • A Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of *** in Healthy Participants. 

  • A Randomized, Parallel, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of *** in Healthy Japanese and Non- Japanese Subjects.

  • Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of *** in Healthy Japanese Participants. 

  • A Phase I Study to Characterize the Pharmacokinetics and Pharmacodynamics of *** Following Administration of Different Multiple-Dose Regimens in Healthy Adult Caucasian and Japanese subjects. 

  • A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability After a Single Dose of *** 

  • A Randomized, Double-Blind. Placebo-Controlled, Multiple-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of *** in Healthy Japanese and Caucasian Subjects. 

  • A Blinded, Safety, Tolerability, and Pharmacokinetic Study of Single Doses of *** in Healthy Japanese Subjects. 

  • A Phase I, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the *** and the *** on the Pharmacokinetics of *** in Healthy Subjects. 

  • A Double-Blind, Randomized, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of *** Drug Product in Healthy Adult Subjects. 

  • Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of *** in Healthy Japanese Participants. 

  • A Phase I, Single-Dose, Open-Label Study to Characterize and Compare the Pharmacokinetics, Safety, and Effect on QTc Interval of *** in Healthy Subjects of Japanese Origin and Healthy Subjects of Non-Asian Origin. 

  • A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies *** and *** vs. Placebo in Healthy Adults. 

  • A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics Of *** In Healthy Japanese And Caucasian Subjects.

  • A Randomized. Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of *** Administered as Intradermal Injection in subjects with Hypertrophic Scar. 

  • Pilot Pharmacokinetics (PK) Bioequivalence (BE) Study of *** versus *** in Healthy Adult Volunteers. (A Randomized, Evaluator-blinded, Single-dose, Two-treatment Two- period, Two-sequence, Crossover, Fasting Study). 

  • A Single-Center, Randomized. Double-Masked Contralateral Evaluation of the Safety and Tolerability After a Single Application and 14 Day Repeated Application of *** Transdermal System (TDS) and Placebo TDS in Adult Subjects with Normal Ocular Health 

  • Randomized, Single-Application, Pivotal Bioequivalence Study to Evaluate the Bioequivalence Transdermal System Compared with *** Transdermal Patch in Healthy Subjects 

  • A Phase I, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of 100 mg, 200 mg and 400 mg of *** in Japanese and Caucasian Healthy Volunteers 

  • A Phase I, Dose-Ranging Study of the Safety, Tolerability. and Pharmacokinetics of *** in Healthy Volunteers 

  • A Randomized, Subject-Blinded, Placebo-Controlled, Single Ascending Dose Study of Subcutaneous *** in Healthy Subjects 

  • A Phase II, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of *** at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease 

  • A Randomized, Multi-Center, Open Label, Parallel Group Study in Postmenopausal Women with Osteoporosis to Evaluate the Noninferiority of Subject-Administered *** via Autoinjector/Pen vs Healthcare Provider-Administered *** for Osteoporosis 

  • A Randomized, Double-Blind. Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered *** After Dosing to Steady-State with Oral *** in Healthy Subjects 

  • A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of *** in Healthy Japanese and Caucasian Subjects 

  • A Comparison of *** to Selective Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension 

  • A Phase 3, Double-Masked, Randomized, Controlled Study of *** Compared to *** in Subjects with Dry Eye Disease 

  • A 4 weeks, Phase II, Multicenter, Randomized, Double-Masked, ***, Parallel Group study with 12 weeks of follow-up to evaluate safety and efficacy of *** versus *** in patient with moderate to severe dry eye (DE) 

  • A Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group *** with Clinical Endpoint Comparing *** in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes 

  • Efficacy, Safety and Pharmacokinetics of *** for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients